Kantarjian et al53 assessed the efficacy and safety of dasatinib, as when compared with imatinib, for the initial-line remedy of CML-CP. 5 hundred and nineteen patients with newly diagnosed CML-CP ended up randomly assigned to get dasatinib in a dose of a hundred mg the moment day-to-day (259 sufferers) or https://luisz963puy7.blogsvila.com/profile